Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay.

ABSTRACT:

Background

Detection of minimal residual disease (MRD) in early breast cancer (EBC) after curative-intent treatment may identify patients at risk for recurrence. Most circulating tumor DNA (ctDNA)-based MRD assays require knowledge of genomic alterations from tumor tissue. However, tissue availability may be limited in some patients. Here, we evaluated sensitivity and specificity for recurrence detection, using a plasma-only ctDNA MRD assay.

Materials and methods

For this pilot study, 47 plasma samples from 38 EBC patients were collected at 12 or 36 months post-diagnosis or at clinical recurrence. ctDNA presence was determined by a custom bioinformatics classifier that identifies tumor-derived somatic variants and methylation profiles specific to individual cancer types usin

SUBMITTER: Janni W 

PROVIDER: S-EPMC11982450 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature